- Home
- BHAT vs CUE Comparison
BHAT vs CUE Comparison
Compare BHAT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHAT | CUE |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 27.8M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BHAT | CUE |
|---|---|---|
| Price | $0.68 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 70.5M | 471.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $0.03 | $0.23 |
| 52 Week High | $3.94 | $1.05 |
Technical Indicators
Market Signals| Indicator | BHAT | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 50.66 | 49.03 |
| Support Level | $0.58 | $0.27 |
| Resistance Level | $0.88 | $0.36 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 35.64 | 48.60 |
Price Performance
Historical ComparisonAbout BHAT Blue Hat Interactive Entertainment Technology
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.